Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relmada Therapeutics, Inc.

0.8349
+0.01491.82%
Post-market: 0.7800-0.0549-6.58%19:29 EDT
Volume:477.71K
Turnover:403.07K
Market Cap:27.71M
PE:-0.33
High:0.9000
Open:0.8231
Low:0.7862
Close:0.8200
Loading ...

Relmada Therapeutics Q4 EPS USD -0.62

THOMSON REUTERS
·
28 Mar

Relmada Therapeutics: Expect Topline Phase 2 Data for Ndv-01 for High-Grade Non-Muscle Invasive Bladder Cancer (Hg-Nmibc)

THOMSON REUTERS
·
28 Mar

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

GlobeNewswire
·
28 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

BRIEF-Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing

Reuters
·
27 Mar

Relmada Therapeutics Inc -on March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing

THOMSON REUTERS
·
27 Mar

BRIEF-Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Reuters
·
25 Mar

Relmada- to Pay up to $200 Mln in Development, Regulatory,Sales Milestones Pending Successful Commercialization

THOMSON REUTERS
·
25 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
22 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
20 Mar

Relmada Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview

Reuters
·
15 Mar

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

Asarina Pharma Ab (Publ) - Signs Asset Purchase Agreement With Relmada Therapeutics

THOMSON REUTERS
·
07 Feb

Relmada Therapeutics acquires Sepranolone from Asarina Pharma

TIPRANKS
·
06 Feb

Relmada Therapeutics Inc - Acquires Sepranolone for EUR 3 Million

THOMSON REUTERS
·
06 Feb

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome From Asarina Pharma Ab

THOMSON REUTERS
·
06 Feb

BRIEF-Relmada Therapeutics Acquires Potential Therapy For Tourette Syndrome From Asarina Pharma AB

Reuters
·
06 Feb

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome From Asarina Pharma Ab

THOMSON REUTERS
·
06 Feb

Relmada Therapeutics: Purchases Sepranolone, for Treatment of Tourette Syndrome and Other Compulsion-Related Conditions From Asarina Pharma Ab

THOMSON REUTERS
·
06 Feb